222 S. Rainbow Blvd
Suite 203
Las Vegas, Nevada 89145

Our Mission

The National Bleeding Disorders Foundation (NBDF) Nevada Chapter is dedicated to finding better treatments and cures for inheritable bleeding disorders and to preventing the complications of these disorders through education, advocacy and research.

News & Events

For Immediate Release 
CONTACT:  
Kyla Clark 
National Bleeding Disorders Foundation 
347-920-0047
kclark@hemophilia.org%C2%A0" title="Email for Kyla Clark">kclark@bleeding.org 

 

NBDF Unveils THRIVE Campaign: Empowering Individuals with Bleeding Disorders through 6 Essential Steps

 

Pfizer recently provided new clinical trial updates for their investigational therapy marstacimab. The data was presented last month at the 2024 annual meeting of the European Hematology Association (EHA) in Madrid. Marstacimab is a laboratory-engineered monoclonal antibody developed to treat hemophilia A and B patients, with or without inhibitors.

 

The National Bleeding Disorders Foundation (NBDF) is excited to announce a new accredited educational opportunity for healthcare providers. This live/virtual program will focus on optimizing non-factor replacement therapy for hemophilia patients. 

 

Advertisements

222 S. Rainbow Blvd
Suite 203
Las Vegas, Nevada 89145

© National Bleeding Disorders Foundation 2024

Crafted by Firespring